Clinical trials in womens cancers

2014年，我成为妇女恶性肿瘤处的代理主任。我们目前正在分析07C0058临床试验的标本和数据-贝伐单抗和索拉非尼2期卵巢癌；卡铂和奥拉帕尼在三个队列患者中的应用：BRCA突变携带者、高级别浆液性卵巢癌、三阴性乳腺癌；贝伐单抗和达沙替尼的09-C-0191期1期研究。我们已经提交了用于卵巢癌的临床试验12C0191 - SMAC-mimetic biinapant 2期的结果。我们目前有三个临床试验开放给患者随访（11C0022 -卡铂和奥拉帕尼在女性癌症中的药代动力学；09C0019 -贝伐单抗和达沙替尼在卵巢癌中的1-2期试验；12C0081 -奥拉帕尼和Cederinib在卵巢癌中的1-2期试验）。我们的两项临床试验目前正在进行：14-C-0156 CHEK抑制剂用于三阴性乳腺癌和高级别浆液性卵巢癌。

In 2014, I became the Acting Director of the Women's Malignancies Branch. We are currently in the process of analyzing specimens and data from clinical trials 07C0058 - Bevacizumab and Sorafenib phase 2 in ovarian cancer; 08C0092 - Carboplatin and Olaparib in three cohort of patients: BRCA mutation carriers, high-grade serous ovarian cancer, triple negative breast cancer; and 09-C-0191 phase 1 study of bevacizumab and dasatinib. We have submitted for publication the results of clinical trial 12C0191 - SMAC-mimetic birinapant phase 2 in ovarian cancer. We currently have three clinical trials open to patient follow up (11C0022 - Pharmacokinetics of Carboplatin and Olaparib in women's cancers; 09C0019 - Bevacizumab and Dasatinib phase 1 trial; 12C0081 - Olaparib and Cederinib in ovarian cancer phase 1-2 trial). Two of our clinical trials are currently open to accrual: 14-C-0156 CHEK inhibitor for women with Triple Negative Breast Cancer and High Grade Serous Ovarian Cancer.